Extended Longevity Clinical Trial Demonstrates Remarkable Reversal of Aging Biomarkers

Revolutionary Study Shows the Safety and Effectiveness of Extended Longevity Protocol in Healthy Individuals

MAUI, Hawaii–(BUSINESS WIRE)–Extended Longevity, a leading provider of innovative anti-aging solutions, is thrilled to announce the successful completion of the groundbreaking Longevinaut Study #1. The study, conducted under the guidance of Dr. Juergen Winkler at Quantum Functional Medicine, Carlsbad, CA, under the supervision of the Institute of Regenerative and Cellular Medicine, of Santa Monica, California, Executive Director Dr. Barbara Krutchkoff, PhD has demonstrated the safety and effectiveness of the Extended Longevity Protocol in reversing the epigenetic aging rate in a cohort of healthy individuals aged 55-75.

The results of this year-long clinical trial have exceeded expectations, providing hope for individuals seeking to improve their quality of life and reduce the risk of age-related diseases. The Extended Longevity Protocol, a set of 10 phytotherapeutic extract formulations targeting the 10 determinant factors of aging, has shown significant success in decelerating the biomarkers of aging across the cohort.

The study involved a rigorous methodology, with participants undergoing epigenome tests, telomere tests, and C-Reactive Protein (CRP) tests at baseline, 6 months, and 12 months. The study conducted by Dr. Winkler revealed astonishing outcomes. The epigenome aging biomarker was decelerated by an average of 13.16 years, or 22.5%, from baseline age, with some participants achieving age deceleration of up to 36.31%. Telomere length, a critical marker of cellular aging, exhibited an average reduction of 8.2% from chronological age, equivalent to a staggering 40-year age deceleration. Additionally, inflammation levels, as measured by the Hs C-RP test, decreased by an average of 55.4% in participants testing positive.

“The results of the Longevinaut Study #1 provide significant evidence of the effectiveness of the Extended Longevity Protocol in reversing the aging process,” said Dr. Winkler. “These findings offer hope for individuals looking to enhance their overall health, well-being, and longevity.”

Extended Longevity’s commitment to providing evidence-based interventions using natural phytotherapeutic extract formulations has paved the way for a potential breakthrough in healthy aging. While further research is required to fully comprehend the benefits and potential risks, these findings indicate a promising approach for promoting longevity and improving the quality of life for aging individuals.

As the aging population continues to grow, the implications of slowing down the aging process and reducing the burden of age-related diseases are immense. Extended Longevity remains dedicated to advancing the field of anti-aging medicine and improving the overall health of individuals through continued research and development.

For more information on the Longevinaut Study #1 and the Extended Longevity Protocol, please visit https://www.extendedlongevity.com/general-8 or contact our media relations team.

About Extended Longevity: Extended Longevity is a leading provider of phytotherapeutic extract formulations designed to address the determinant factors of aging. Backed by proven clinical studies, our products offer a natural and evidence-based approach to promote healthy aging safely. With a commitment to research and innovation, Extended Longevity is dedicated to improving the quality of life for individuals seeking to reverse the aging process.

Contacts

Media Contact:
Steven M. Schorr, CEO Extended Longevity, Inc.

Phone: (844) 420-0193

Email: [email protected]